What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort

Read full text
Authors: Ivan Foeldvari, Kathryn Torok, Ozgur Kasapcopur, Amra Adrovic, Brian Michael Feldman, Flavio Sztajnbok, Maria Teresa Terreri, Ana Paula Sakamoto, Sindhu Johnson, J Bauer Anton, Valda Stanevicha, Archana Khan
+38 more Dieneke Schonenberg‐Meinema, Eslam Al-Abadi, Ekaterina I. Alexeeva, MM Katsicas, Sujata Sawhney, Vanessa Smith, Simone Appenzeller, Tadej Avcin, Mikhail Kostik, Thomas Lehman, Hana Malcová, Edoardo Marrani, Clare E Pain, Anjali Patwardhan, Walter-Alberto Sifuentes-Giraldo, Natalia Vasquez‐Canizares, Patrícia Costa-Reis, Mahesh Janarthanan, Monika Moll, Dana Němcová, María José Santos, Sima Abu Al-Saoud, C G Battagliotti, Lillemor Berntson, B. Bica, Juergen Brunner, Despina Eleftheriou, Liora Harel, Gerd Horneff, Daniela Kaiser, Tilmann Kallinich, Dragana Lazarević, Kirsten Minden, Susan Nielsen, Farzana Nuruzzaman, Siri Opsahl Hetlevik, Yosef Uziel, Jens Klotsche
Cited by: 1
References: 23

Abstract

Objectives: Clinical trial data are lacking for treatment of patients with juvenile systemic sclerosis (jSSc). Three published recommendations exist for jSSc but real-world data on treatment patterns are lacking. The aim of this study was to analyse treatments used in the jSSc inception cohort (jSSci) and compare to published recommendations on the treatment of jSSc. Methods: Data was extracted for patients with 24 months follow-up visits in the jSSci up until June 2023. Medications used and their association with clinical characteristics were analysed. Logistic regression analyses were performed to compare treatments between limited and diffuse cutaneous jSSc subtypes, organ involvement and time of initiation of treatment. Multilevel mixed effects logistic regression analyses were used to evaluate the change in medication use in follow-up. Treatment patterns were compared against published recommendations. Results: 93 patients had 24 months follow-up data. 77% of patients were receiving disease-modifying treatment (DMARD) at enrolment, which increased to 91% at 24 months (p

Fields of Study & Subjects

Systemic Sclerosis and Related Diseases Adolescent and Pediatric Healthcare Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
Journal of Scleroderma and Related Disorders
Publisher
BMJ
Volume
11
Issue
1
Pages
e000010–e000010
Publication date
1 May 2026
Language
EN